New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints

Wang, Victoria E.; Grandis, Jennifer R.; Ko, Andrew H.

doi:10.1158/1078-0432.ccr-16-0292

Cited by 30 publications

(26 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative chemotherapy with FP can be regarded as standard treatment for patients with stage II/III esophageal squamous cell carcinoma (ESCC) . Furthermore, an antitumor effect is expected with the development of a combination therapy comprising a triplet regimen, molecular targeted drug, and immunity checkpoint inhibitor . Efforts to achieve individualized treatment by genetic analysis have also begun in the presence of differences in histopathological type between Caucasians and Asians.…”

Section: Introductionmentioning

confidence: 99%

Recent advancements in esophageal cancer treatment in Japan

Tanaka

Yoshida

Suetsugu

et al. 2018

Annals of Gastroent Surgery

View full text Add to dashboard Cite

The 11th edition of the Japanese Classification of Esophageal Cancer (EC) was published in 2017. Some correction was made in the depth of tumor invasion to be consistent with the TNM classification by the Union for International Cancer Control (UICC). With regard to surgery, short‐term safety and long‐term effectiveness under thoracotomy/video‐assisted thoracoscopic surgery are expected to be proven by the Japan Clinical Oncology Group (JCOG)1409 study. Results of nutritional management and countermeasures for adverse events not only during the perioperative period but also during EC chemotherapy were reported. From now on, the pursuit of low invasiveness and radicality is desired. Esophageal surgery is also expected to be safe at all institutions. To determine the optimal modality of preoperative treatment and a novel chemo(radio)therapy regimen for patients with distant metastasis, the results of the ongoing JCOG1109 and 0807 studies are being released. The effect of the addition of molecular targeted drugs on chemotherapy and concurrent chemoradiation has not yet improved overall survival. Immune checkpoint inhibitor drugs could offer a potential new treatment approach for patients with treatment‐refractory advanced squamous cell carcinoma (SCC). The Cancer Genome Atlas Research Network reported the results of a comprehensive genome analysis and molecular analysis of SCC and adenocarcinoma of the esophagus. Further differentiation of SCC and adenocarcinoma by molecular characterization analysis may be useful for the development of clinical trials and targeted drug therapies as precision medicine. The era of ultimate minimally invasive surgery and personalized treatment has begun. Large, prospective studies will be required to confirm the value of these advancements.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent advancements in esophageal cancer treatment in Japan

Tanaka

Yoshida

Suetsugu

et al. 2018

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

“…[45][46][47] So far, among the few dozens of targeted agents trialled in the EAC, only two agents have been approved for treatment in the metastatic setting, the anti-HER2 monoclonal antibody trastuzumab and ramucirumab, a recombinant antibody that binds vascular endothelial growth factor receptor 2 (VEGFR-2). 48 Despite positive oncological trials, an average survival advantage from the addition of these agents to standard palliative chemotherapy is 2 months, with substantially increased toxicity. 49,50 This calls for a novel approach to usefully classify EAC in order to inform therapeutic management.…”

Section: Genomics Mutations and Deregulated Pathwaysmentioning

confidence: 99%

Molecular landscape of esophageal cancer: implications for early detection and personalized therapy

Talukdar

Pietro

Secrier

et al. 2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Esophageal cancer (EC) is one of the most lethal cancers and a public health concern worldwide, owing to late diagnosis and lack of efficient treatment. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are main histopathological subtypes of EC that show striking differences in geographical distribution, possibly due to differences in exposure to risk factors and lifestyles. ESCC and EAC are distinct diseases in terms of cell of origin, epidemiology, and molecular architecture of tumor cells. Past efforts aimed at translating potential molecular candidates into clinical practice proved to be challenging, underscoring the need for identifying novel candidates for early diagnosis and therapy of EC. Several major international efforts have brought about important advances in identifying molecular landscapes of ESCC and EAC toward understanding molecular mechanisms and critical molecular events driving the progression and pathological features of the disease. In our review, we summarize recent advances in the areas of genomics and epigenomics of ESCC and EAC, their mutational signatures and immunotherapy. We also discuss implications of recent advances in characterizing the genome and epigenome of EC for the discovery of diagnostic/prognostic biomarkers and development of new targets for personalized treatment and prevention.

show abstract

“…Insights from Signaling Pathways and Immune Checkpoints" in the section of "CCR New Strategies" (1). In this manuscript, Wang et al first presented the current status of esophageal cancer, introduced conventional treatment strategies, and then focused on targeted therapy of this deadly disease.…”

Section: Clinical Cancer Research Has Recently Published a Review Artmentioning

confidence: 99%